Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Farydak: multiple myeloma after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

In combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior regimens, including BTZ and an immunomodulatory agent.

Broader topic: Multiple Myeloma

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      who have received at least 2 prior regimens
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Farydak (panobinostat) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
    source wording
    In combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior regimens, including BTZ and an immunomodulatory agent.

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice